Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists

An anti-angiogenesis and agent technology, applied in biochemical equipment and methods, anti-animal/human immunoglobulin, drug combination, etc., can solve problems such as incomplete response to bevacizumab

Inactive Publication Date: 2016-11-16
F HOFFMANN LA ROCHE & CO AG
View PDF128 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, as in previous studies of angiogenesis inhibitors, some of these Phase III studies have shown that a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
  • Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
  • Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0577] Example 1: Combination anti-VEGF+anti-OX40 treatment exhibits greater efficacy than single agent treatment

[0578] Combining different modalities of cancer therapy can lead to beneficial effects on tumor growth. As described below, anti-VEGF treatment resulted in decreased tumor growth compared to anti-GP120 (control) treated mice. Anti-OX40 treatment alone exhibited little activity. Surprisingly, anti-OX40 treatment in combination with anti-VEGF treatment exhibited superior tumor growth inhibition compared to single agent administration or anti-GP120 treatment despite having little antitumor activity on its own. Without wishing to be bound by theory, it is hypothesized that the synergistic increase in activity observed for combined anti-VEGF + anti-OX40 treatment may be due to increased intratumoral dendritic cell activation induced by anti-VEGF treatment.

[0579] The results described herein suggest that sequential anti-OX40 treatment with anti-VEGF administration...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The disclosure provides compositions and methods for treating cancers. The method comprises administering an anti-angiogenesis agent and an OX40 binding agonist.

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Application Serial No. 61 / 973,193, filed March 31, 2014; U.S. Provisional Application Serial No. 61 / 989,448, filed May 6, 2014; Serial No. 62, filed October 31, 2014 Priority of U.S. Provisional Application Serial No. 62 / 080,171 filed November 14, 2014; and U.S. Provisional Application Serial No. 62 / 113,345 filed February 6, 2015, by reference to Each of them is included in this article in its entirety. [0003] sequence listing [0004] The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: Sequence Listing in Computer Readable Format (CRF) (File Name: 146392031540SEQLIST.txt, Date of Record: March 26, 2015, Size: 188KB). field of invention [0005] The present invention relates to methods of treating cancer by administering anti-angiogenic agents and OX40 binding agonists. Background of the invention [0006] Angiogen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K39/395A61K48/00A61K47/48C07K16/30C07K16/22C07K16/28
CPCA61K39/3955A61K39/39558A61K45/06A61K48/00C07K16/22C07K16/2878C07K16/30C07K16/3069A61K2039/507C07K2317/75C07K2317/76C07K2317/92C07K2317/515C07K2317/51C07K2317/56C07K2317/71A61K47/6803A61K47/6849A61P35/00A61P43/00A61K2039/505C12N15/63C12N15/70C12N2800/00C12N15/79C12N5/10C12N15/64C07K16/3015C07K16/3023C07K16/303C07K16/3038C07K16/3046C07K2317/21C07K2317/24C07K2317/732
Inventor K·沃尔什P·德阿梅达杜常春J·金J·朱J·贝弗斯三世J·安德亚Y·沈
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap